Stock Code: 603707 Stock Abbreviation: King-friend Pharma Announcement No.: 2026-042

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.

Announcement on the Approval by the U.S. FDA of the Subsidiary's Product Insulin Aspart Injection

The Board of Directors and all directors of the Company warrant that there are no false records, misleading statements or material omissions in the contents of this announcement, and they shall bear individual and joint and several legal liability for the truthfulness, accuracy and completeness of its contents.

Emerge Bioscience Pte. Ltd. ("Emerge"), a wholly-owned subsidiary of Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as "King-friend Pharma" or the "Company"), has recently received from the U.S. Food and Drug Administration (hereinafter referred to as the "U.S. FDA") a BLA approval letter for Insulin Aspart Injection (BLA No.: 761497/Original 1). The relevant details are hereby announced as follows:

I. Basic Information about the Drug

(I) Drug Name	Insulin Aspart Injection
(II) Indication	For the improvement of glycemic control in adult and pediatric patients with diabetes mellitus.
(III) Dosage Form	Injection
(IV) Strengths	10 mL (100 units/mL) multiple-dose vial injection (for intravenous use), 10 mL (100 units/mL) multiple-dose vial injection (for subcutaneous use), and 3 mL (100 units/mL) single-use prefilled subcutaneous injection pen.
(V) BLA No.	761497/Original 1
(VI) Applicant	Emerge Bioscience Pte. Ltd

II. Other Relevant Information about the Drug

On July 24, 2026, Emerge, a wholly-owned subsidiary of the Company, received the formal approval letter from the U.S. Food and Drug Administration (FDA). The Biologics License Application (BLA, Application No.: BLA 761497/Original 1) submitted by Emerge for Insulin Aspart Injection has been approved by the U.S. FDA for marketing. The approved strengths include 10 mL (100 units/mL) multiple-dose vial injection (for intravenous use), 10 mL (100 units/mL) multiple-dose vial injection (for subcutaneous use), and 3 mL (100 units/mL) single-use prefilled subcutaneous injection pen.

In terms of market space, according to the Diabetes Atlas (11th edition) of the International Diabetes Federation (IDF), in 2024 the number of adults aged 20-79 with diabetes in the United States was approximately 38.54 million, with a prevalence rate of 15.7%; the country's total diabetes-related health expenditure reached USD 404.5 billion, with per capita health expenditure of USD 10,497, ranking among the highest in the world. Institutions forecast that by 2050, the diabetic population in this age group in the United States will increase to 43

million. In addition, according to the 2024 annual report of the American Diabetes Association (ADA), approximately 7.7 million people with diabetes in the United States require insulin injection therapy, indicating a relatively large existing market demand for insulin in the United States.

As of the date hereof, the Company has invested approximately RMB 19,959.07 ten-thousand yuan (approximately RMB 199.59 million) in research and development expenses for the Insulin Aspart Injection project.

III. Impact on the Company

The approval of Insulin Aspart Injection by the U.S. FDA will further enhance the Company's international influence, enrich the Company's international market product line, and improve the Company's competitiveness in the international market. If the product is subsequently launched and sold in the U.S. market, it is expected to have a positive impact on the Company's operating performance.

IV. Risk Warning

The newly approved product has not yet been launched or sold in the United States and will have no material impact on the Company's operating performance in the short term. Future sales may be affected by factors such as the overseas market environment, sales channels and exchange rate fluctuations, and there is considerable uncertainty. All investors are advised to make cautious decisions and pay attention to the prevention of investment risks.

It is hereby announced.

Board of Directors of Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.

July 28, 2026